secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncternal Therapeutics, Inc. (—)
CIK:        0001260990
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127184
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Oncternal Therapeutics cuts remaining workforce; retains 4 part-time employees for strategic alternatives
--------------------------------------------------------------------------------

- Workforce reduction of all remaining employees effective Dec 2, 2024; only 4 retained part-time.
- Estimated severance and termination costs of ~$2.4M, primarily recognized in Q4 2024.
- CEO James B. Breitmeyer and officer Richard G. Vincent transition to 50% part-time effective Dec 2.
- Board unanimously approved reduction on Nov 13; company exploring strategic alternatives, including sale or dissolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/onct-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer